These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Third Tysabri adverse case hits drug class. Sheridan C Nat Rev Drug Discov; 2005 May; 4(5):357-8. PubMed ID: 15902765 [No Abstract] [Full Text] [Related]
14. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis. Berger T; Deisenhammer F N Engl J Med; 2005 Oct; 353(16):1744-6; author reply 1744-6. PubMed ID: 16236749 [No Abstract] [Full Text] [Related]
15. Reply to "'Thinking without thinking' about natalizumab and PML". Houff S; Berger JR J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798 [No Abstract] [Full Text] [Related]
16. Natalizumab: a double-edged sword? DeAngelis LM Ann Neurol; 2009 Sep; 66(3):262-3. PubMed ID: 19798644 [No Abstract] [Full Text] [Related]
17. Does the flap of a butterfly's wings in Brazil set off a tornado in Texas?--The JC Virus Story in multiple sclerosis. Achiron A; Miron S; Shoenfeld Y Isr Med Assoc J; 2005 May; 7(5):283-5. PubMed ID: 15909458 [No Abstract] [Full Text] [Related]
18. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Ko MY; Stefoski D; Balabanov R Neurology; 2011 Sep; 77(10):1020; author reply 1020. PubMed ID: 21893676 [No Abstract] [Full Text] [Related]
19. The trials and tribulations of Tysabri. Lancet Neurol; 2006 May; 5(5):373. PubMed ID: 16632299 [No Abstract] [Full Text] [Related]